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Introduction: COVID-19 is a new disease which provokes damage to human health, with 
direct impact on the cardiovascular system.  
Objective: to describe the pathophysiogenic mechanisms involved in the cardiovascular 
damage in COVID-19 patients. 
Method:  a literature review was carried out, through articles retrieved in PubMed, SciELO, 
EBSCO and ClinicalKey, using 27 references.  
Development:  different pathophysiogenic mechanisms are associated with cardiovascular 
damage in COVID-19 patients; among them direct myocardial injury, viral invasion of 
cardiomyocytes, alteration of myocardial supply-demand index, atheroma-plaque rupture and 
coronary thrombosis, systemic inflammation and electrolyte imbalances.  
Conclusions: determining the mechanisms involved in cardiovascular damage is a 
fundamental pillar as a preventive and screening strategy in COVID-19 patients. Inflammatory 
response, secondary hemodynamic changes to the viral process, as well as hypoxemia, are 
mechanisms of negative impact on cardiovascular health, leading to the development of acute 
cardiac injury. 
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Introducción: la COVID-19 es una enfermedad nueva con repercusión directa sobre el 
sistema cardiovascular. 
Objetivo: describir los mecanismos fisiopatogénicos involucrados en el daño cardiovascular 
en pacientes portadores de COVID-19. 
Métodos: se realizó una revisión bibliográfica, mediante artículos recuperados en PubMed, 
SciELO, Ebsco y ClinicalKey. Se emplearon 27 referencias.  
Desarrollo: diferentes mecanismos fisiopatológicos se asocian al daño cardiovascular en 
pacientes con COVID-19, entre ellos la injuria miocárdica directa, invasión viral de los 
cardiomiocitos, alteración del índice suministro-demanda del miocardio, ruptura de la placa 
de ateroma y trombosis coronaria, inflamación sistémica, desequilibrios hidroelectrolíticos. 
Conclusiones: determinar los mecanismos involucrados en el daño cardiovascular es un pilar 
fundamental como estrategia preventiva y de tamizaje en estos pacientes. La respuesta 
inflamatoria, los cambios hemodinámicos secundarios al proceso viral, así como la hipoxemia, 
constituyen mecanismos de repercusión negativa sobre la salud cardiovascular, llevando al 
desarrollo de lesión cardiaca aguda. 
 






Coronaviruses (CoVs) are non-segmented positive chain RNA viruses with a genome 
surrounded by a protein layer. Most CoVs cause disease in their particular host species; those 
that can infect humans through cross-species transmission have become a major public health 
threat.(1) 
 
After the SARS-CoV (Severe Acute Respiratory Syndrome- CoronaVirus) of 2003 and the 
MERS-CoV (Middle East Respiratory Syndrome- CoronaVirus) of 2009, humanity has been 
attacked again by another coronavirus in 2020, the SARS-CoV-2, and in February of this year 
the World Health Organization (WHO) named the disease produced by this agent: COVID-19 
(coronavirus disease-2019). It was detected for the first time in China, in December 2019, in 
Wuhan, capital of Hubei province.(2) 
 
This new virus has been reported to spread by air, through Flügge micro-drops emitted from 
infected people and through contact, whereby it spreads from one person to another or 
through contact with some contaminated material. More severe patients present symptoms of 
viral pneumonia including fever, breathing difficulties and bilateral impregnation of the lungs. 
(1) 
 
SARS-CoV-2 belongs to the subfamily Orthocoronavirinae, genus Coronavirus and to the 
subgenus Sarbecovirus (beta-coronavirus) and within them to lineage 2. The genome of SARS-
CoV-2 consists of a single-stranded RNA of about 30,000 nucleotides and six ORF (open 
reading frames), identical to the rest of the coronaviruses, and several additional genes. Most 
of these genes only have 80% homology to the former SARS-CoV virus; however, the genes 
involved in the replication have 94% homology to this virus.(3) On March 11, 2020, due to the 
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Since the beginning of the current coronavirus outbreak, there has been great concern about 
a disease that has rapidly spread in several regions of the world, with different impacts. By 
March 18, 2020, confirmed positive cases of COVID-19 had already exceeded 214,000 
worldwide.(5) 
 
By the end of March, the number of confirmed positive patients exceeded 775,000 in more 
than 160 countries, and the number of people infected was probably higher. Until then, more 
than 360,000 people had died from the disease.(6) 
 
According to official data from the WHO, by April 12, 2020, more than 1, 700 000 million cases 
of COVID-19 had been confirmed worldwide, and deaths exceeded 110,000. In the Americas, 
the number of confirmed positive cases was 644,986, and more than 25,000 deaths were 
reported.  In Cuba, until that date, 726 cases had been confirmed, of which 21 (2.89 %) died, 
and 121 (16.6 %) were discharged from the hospital. (7) 
 
In the pathogenesis of SARS-CoV-2 infection it has been suggested the recognition of the 
angiotensin-converting enzyme 2 (ACE 2) by the S protein of the virus; which is primed by 
the serin-2 trans-membrane cell protease (TMPRSS 2), facilitating the entry and spread in the 
receptor cells. ACE 2 is widely expressed in type II pulmonary alveolar cells and capillary 
endothelial cells. In addition, alveolar cells express TMPRSS2. This explains why COVID-19 is 
presented as a severe respiratory disease. (8) 
 
Infection of the lung by this virus leads to a cytokine storm with elevated levels of pro-
inflammatory cytokines, resulting in edema, air exchange dysfunction, acute respiratory 
distress and secondary infection, which can result in death. The expression of ACE 2 is also 
seen in other extra-pulmonary tissues, such as the heart. Such a pattern of expression 
explains why infected patients in intensive care suffer not only from acute respiratory distress 
syndrome, but also from other cardiovascular complications. 
 
Although COVID-19 typically presents with symptoms of a lower respiratory tract infection, a 
significant proportion of patients experience cardiovascular symptoms at the initial 
presentation of the disease. (9) 
 
Due to the great threat COVID-19 represents at present, together with the existence of a wide 
dispersion in the scientific literature of contents; the present research is aimed at describing 





Among the patients confirmed with SARS-CoV-2 infection by the National Commission of China 
(NHC), many of the patients demanded medical attention for presenting cardiovascular 
symptoms such as palpitations and chest pain. Among those who died, 11,8 % of the patients 
without underlying cardiovascular disease had significant heart damage, with elevated levels 
of high-sensitivity troponins or cardiac arrest during their hospital stay.(10) 
 
Although the respiratory tract is the primary target for SARS-CoV-2, the cardiovascular system 
is affected in different ways. There are different pathophysiogenic mechanisms involved in the 
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Direct myocardial injury 
 
SARS-CoV-2 enters human cells by binding to ACE 2, which is highly expressed in the heart 
and lungs. ACE 2 plays an important role in the neurohumoral regulation of the cardiovascular 
system in normal health status, as well as in various nosological entities. Fixation of SARS-
CoV-2 to ACE 2 may result in alteration of ACE 2 signaling pathways, leading to acute 
myocardial and pulmonary injury.(12) 
 
Viral invasion of cardiomyocytes 
 
SARS-CoV-2 can invade myocytes and cause direct damage.(13) According to Bansal (14) this is 
supported by previous autopsy studies in patients who had died of SARS during its outbreak 
in Toronto. In this study, viral RNA was detected in autopsies in 35 % of the hearts sampled, 
evidencing direct myocardial injury from the virus. 
 
Alteration of the supply-demand index of myocardium 
 
The increased cardio-metabolic demand associated with systemic infection coupled with 
hypoxia caused by acute respiratory disease can impair the oxygen supply-demand ratio of 
the myocardium. This event can lead to acute injury to the myocardium secondary to that 
hypoxia. (14) 
 
Rupture of atheroma plaque and coronary thrombosis 
 
Systemic inflammation, as well as stress due to increased coronary blood flow, can precipitate 
the rupture of atheroma plaque. This, together with the alteration of the supply-demand index 
of myocardium leads to the occurrence of ischemic events, mainly acute myocardial infarction. 
The prothrombotic environment created by systemic inflammation also increases the risk of 
infarction.(14) 
 
In a meta-analysis (15) it was reported that, among patients requiring intensive care (20,3 %), 
13 % presented ischemic events, and of them 13,9 % died. 
 
In a study in Italy,(16) more than two-thirds of patients who died from COVID-19 had diabetes 
or a history of ischemic heart disease. Acute myocardial infarction has been recognized as an 
important factor in the prognosis of viral disease, having suffered a heart attack increases the 




The most severe forms of COVID-19 are characterized by acute systemic inflammatory 
response and cytokine storm, which can result in multiple organ injury leading to multi-organ 
failure. Studies have shown high circulatory levels of pro-inflammatory cytokines in patients 




Electrolyte imbalances can occur in any critical systemic disease and can precipitate 
arrhythmias, especially in patients with a history of heart conditions. There is particular 
interest in hypokalemia in COVID-19, due to the interaction of SARS-CoV-2 with the renin-
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angiotensin-aldosterone system. Hypokalemia increases vulnerability for various 
tachyarrhythmias.(19) 
 
It is difficult to outline the spectrum of cardiovascular presentations of COVID-19. However, 
based on the available evidence, it appears that cardiovascular sequelae may range from 
cardiac arrhythmias, acute myocardial injury, myocarditis, and acute coronary syndrome to 
cardiac collapse and cardiogenic shock.(20) 
 
Several reports (10, 15, 16) have noted the incidence and types of adverse cardiovascular events 
associated with COVID-19. In one study (21) conducted in China, arrhythmias were present in 
16,7 % of hospitalized patients; and 7,2 % experienced acute cardiac injury.  
 
Cardiac injury, defined as a greater than 99th percentile detection of high-sensitivity troponin-
I blood levels or the presence of new electrocardiographic or echocardiographic abnormalities, 
occurred in 19,7 % of patients. These events were more prevalent among older patients and 
those with associated comorbidities. (21) 
 
According to Ferrari et al., (22) the 26% of the patients hospitalized at Zhongnan University 
Hospital in Wuhan required intensive cardiovascular care. Out of them, 16.7 % developed 
arrhythmias and 7,2 % an acute coronary syndrome. According to Fooy et al;(23) the clinical 
observations suggest cardiovascular complications are an important cause, as well as a 
significant risk factor of mortality in COVID-19 patients.  
 
Enay et al. (24), in an analysis of 41 COVID-19 patients, the complications included acute 
respiratory failure (29 %), acute cardiac injury (12 %) and secondary infections (12 %).  
 
Another study (25) published from the retrospective analysis of the database from two hospitals 
in Wuhan (Jin Yin and Tongii), evaluated 150 confirmed positive cases of SARS-CoV-2, where 
68 (48 %) died. Of the patients who died, 63 % presented underlying diseases, with a 
predominance of cardiovascular diseases.  In those patients with associated cardiovascular 
diseases the risk of death increased.  
 
Palacios-Cruz et al. (26) referred the greatest mortality rate in patients who passed the fifth 
decade of life, where the presence of comorbidities (cardiac, stroke and diabetes) increased 
this risk, along with the susceptibility to get ill. 
 
Management of patients with cardiovascular disease and COVID-19 
 
It results important, before the presence of cardiovascular symptoms, to treat the patient as 
at risk with possible COVID-19 infection, up to rule it out by means of the molecular diagnosis. 
Several studies have reported (10,15,16,27) the presence of patients in the doctor’s offices 
referring cardiovascular symptoms, without respiratory symptoms, who were subsequently 
diagnosed with COVID-19.  
 
In the process of COVID-19 management, a rigorous care must be given to both pulmonary 
and cardiovascular injuries. The early identification, effective and timely treatments, 
maintenance of the hemodynamic and electrophysiological balance is of great significance in 
the effective treatment and long-term prognosis of these patients.(27) 
 
The generalities regarding the management of COVID-19 patients, who develop cardiovascular 
complications or suffer from diagnosed cardiovascular diseases, do not differ from the 
standard management of a non-COVID-19 patient, according to the guidelines established in 
the medical practice.(28, 29)      
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An aspect to consider is to avoid the unnecessary use of diagnostic tests (cardiac troponins 
and echography); if they are not necessary, likewise the randomization of troponins and 
natriuretic peptides must be evaded.(27, 29, 30) 
 
Similarly, the medical literature is against discontinuing the therapy with angiotensin-
converting enzyme inhibitors (ACEI) and of the angiotensin-receptor antagonists (ARA). 
(31,32,33) 
 
The Cuban National Health System works taking into account the individualized care of 
patients, under the precept that there are no diseases, but sick people.  The guidelines and 
information with respect to the management of patients suffering from cardiovascular 
conditions with COVID-19 or cardiovascular damage secondary to COVID-19 are under 




Different pathophysiogenic mechanisms are associated with cardiovascular damage in COVID-
19 patients; among them direct myocardial injury, viral invasion of cardiomyocytes, and 
alteration of myocardial supply-demand index, atheroma-plaque rupture, coronary 
thrombosis, systemic inflammation along with electrolyte imbalances. The inflammatory 
response, secondary hemodynamic changes to the viral process, as well as hypoxemia, 
constitute mechanisms of negative repercussion on the cardiovascular disease, leading to the 
onset of an acute cardiac injury. The early diagnosis of a cardiovascular disease, based on 
knowledge in relation to the different pathophysiogenic mechanisms constitutes an essential 
tool for the prognosis of COVID-19 patients.   
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